ClinicalTrials.gg
Active, not recruitingNCT04735016Updated Nov 12, 2026

DiamondTemp Global Registry

An observational study in Arrhythmia, sponsored by Medtronic Cardiac Ablation Solutions. Active, not recruiting at 21 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Medtronic Cardiac Ablation Solutions (part of Medtronic) · Observational

Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
545
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 40 studies in Arrhythmias, Cardiac by Medtronic — 4 open to participants now, 6 under way, none of them phase 3. Arrhythmias, Cardiac · Medtronic.

Planned enrollment
10th of 23
545 · median 370
Started
2021
the only one that year
Observational
23 of 40
1 open now
Registered
35th of 40
by date

Among the 40 studies in Arrhythmias, Cardiac by Medtronic, this one is the 10th largest by planned enrollment of the 23 observational ones that give a count, is the only one that started in 2021, is one of 23 observational ones, and was the 35th registered.

Arrhythmias, Cardiac

1,051 studies on the registry are indexed under Arrhythmias, Cardiac; 235 are open to participants now.

Browse Arrhythmias, Cardiac studies →

Open to participants now

4 of the 40 studies in Arrhythmias, Cardiac by Medtronic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 166 Arrhythmias, Cardiac studies recruiting now, 118 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Arrhythmias, Cardiac by Medtronic, or all of them as a file.
02

Study summary

The DiamondTemp™ Global Registry is a prospective, global, multi-center, observational post-market registry.

Read the detailed description

The DiamondTemp™ Global Registry is a prospective, global, multi-center, observational post-market registry. The purpose of this clinical study is to describe clinical performance and safety data in a broad patient population treated with the commercially available DiamondTemp™ Family of Cardiac Ablation Catheters (hereafter referred to as the DiamondTemp™ Ablation System) and followed according to the standard of care at each respective institution. The follow up period is intended to align with standard practice and subjects will be followed for a minimum of 12 months post-procedure.

03

Conditions studied

  • Arrhythmia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects ≥ 18 years of age (or minimum age as required by local regulations) who have a recommendation for an ablation with the DiamondTemp™ Ablation System may be approached regarding enrollment in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥ 18 years of age or minimum age as required by local regulations
  • Planned procedure using commercially available DiamondTemp™ Ablation System
  • Willing to comply with study requirements and give IC (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements

Exclusion criteria

Exclusion Criteria:

  • Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager
  • Subject with exclusion criteria required by local law
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
545 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Treatment Arm

    Patients enrolled and treated with the DiamondTemp™ Ablation System

    Device: DiamondTemp™ Ablation System

Interventions

  • DeviceDiamondTemp™ Ablation System

    A cardiac ablation will be performed using the DiamondTemp™ Ablation System.

06

What researchers measure

Primary outcomes

  1. Freedom from Recurrence at 12 Months

    Estimate the 12-month freedom from recurrence of the arrhythmia(s) treated at the study index ablation procedure using the DiamondTemp™ Ablation System.

    Time frame: 12 Months

  2. Freedom from Device / Procedure Related Adverse Events

    Estimate serious device and serious procedure-related adverse events for ablation using the DiamondTemp™ Ablation System through 12 months.

    Time frame: 12 Months

07

Study locations

21 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Dec 2026, 68 months after the start.

Of 69 industry-sponsored observational studies under Arrhythmias, Cardiac, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 68 months is above that.

Counting every sponsor, half of 259 studies reached it within 38 months; a quarter within 16 and three quarters within 97.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Mar 2031 → Dec 2026 and completion Mar 2031 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2021
First posted
Feb 2, 2021
StartActual
Apr 22, 2021
Primary completionEst.
Dec 31, 2026was Mar 2031
CompletionEst.
Dec 31, 2026was Mar 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2031→Dec 31, 2026
Nov 12, 2026
Study completion
Mar 2031→Dec 31, 2026
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Mar 2031→Dec 31, 2026
    Study completion Mar 2031→Dec 31, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04735016
Responsible party
Sponsor
First posted
Feb 2, 2021
Start date
Apr 22, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion